Evidence map›Paper›PMID 40711826›Full record

ArticleJournal of the American Society of Nephrology : JASN2026

Overexpression of Thrombomodulin in Adipose-Derived Mesenchymal Stem Cells Reduces Thrombogenic Risk and Enhances Therapeutic Efficacy.

Yoshiki Tanaka, Ayumu Nakashima, Naoki Ishiuchi, Kisho Miyasako, Keisuke Morimoto, Maria Yoshida, Kensuke Sasaki, Satoshi Maeda, Go Matsuda, Takao Masaki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yoshiki TanakaDepartment of Nephrology, Hiroshima University Hospital, Hiroshima, Japan.
Ayumu NakashimaDepartment of Nephrology, Hiroshima University Hospital, Hiroshima, Japan.ORCID 0000-0002-7838-1494
Naoki IshiuchiDepartment of Nephrology, Hiroshima University Hospital, Hiroshima, Japan.
Kisho MiyasakoDepartment of Nephrology, Hiroshima University Hospital, Hiroshima, Japan.ORCID 0009-0004-1280-8135
Keisuke MorimotoDepartment of Nephrology, Hiroshima University Hospital, Hiroshima, Japan.
Maria YoshidaDepartment of Nephrology, Hiroshima University Hospital, Hiroshima, Japan.ORCID 0000-0001-9628-165
Kensuke SasakiDepartment of Nephrology, Hiroshima University Hospital, Hiroshima, Japan.ORCID 0000-0001-5899-0885
Satoshi MaedaDepartment of Stem Cell Biology and Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Go MatsudaDepartment of Stem Cell Biology and Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Takao MasakiDepartment of Nephrology, Hiroshima University Hospital, Hiroshima, Japan.ORCID 0000-0003-4271-9964

Funding

Japan Agency for Medical Research and Development JP23bk0104124Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Young Scientists JP22K16220
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ischemia-reperfusionprogression of renal failurerenal fibrosisstem cellthrombosis

Identifiers

PMID40711826
PMCPMC12807147

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.